Document is current
Any future updates will be listed below
-
Authors
Dikovskaya, Dina https://orcid.org/0000-0003-3161-3072
Pemberton, Rebecca
Taylor, Matthew https://orcid.org/0000-0002-4003-3128
Tasegian, Anna
Bhattacharya, Purbasha https://orcid.org/0009-0009-5012-0303
Zeneviciute, Karolina https://orcid.org/0000-0002-9628-3783
Sammler, Esther M https://orcid.org/0000-0003-3218-7116
Howden, Andrew J M https://orcid.org/0000-0002-4332-9469
Alessi, Dario R https://orcid.org/0000-0002-2140-9185
Swamy, Mahima https://orcid.org/0000-0003-3977-3425
-
Funding
Funding for this research was provided by:
UKRI | Medical Research Council (MC_UU_00018/1)
UKRI | Medical Research Council (MC_UU_00038/7)
Wellcome Trust (206246/Z/17/Z)
Wellcome Trust (218520/Z/19/Z)
Interline Therapeutics
Chief Scientist Office (SCAF/18/01)
- License Information
-
More Information
Article History
Received: 14 August 2024
Revised: 17 April 2025
Accepted: 30 April 2025
First Online: 20 May 2025
Disclosure and competing interests statement
: MS received research funding from Interline Therapeutics for this study. The authors declare no other conflicts of interest. AT is currently an employee of Amphista Therapeutics Ltd. MT is currently an employee of GlaxoSmithKline. The funders did not play a role in the conceptualisation, design, data collection, analysis, or preparation of the manuscript.
